Apollo Commercial Real Estate Finance (ARI) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
20 Feb, 2026Executive summary
A proposed transaction involves the sale of approximately $9 billion in commercial mortgage loans to Athene, pending shareholder approval.
The transaction is expected to provide attractive yields and conservative loan-to-values, with spreads 50–75 basis points higher than new issuances.
Forward-looking statements highlight potential risks, including market trends, interest rates, and the ability to complete the transaction as planned.
Voting matters and shareholder proposals
Shareholders are being solicited to approve the proposed transaction involving the sale of commercial mortgage loans.
Proxy materials and other relevant documents will be filed with the SEC and made available to shareholders at no cost.
Board of directors and corporate governance
The independent Audit Committee of the Board was involved in the transaction process, with third-party pricing validation provided.
Directors and executive officers may be considered participants in the proxy solicitation.
Latest events from Apollo Commercial Real Estate Finance
- $8.8B loan portfolio, 9.4% yield, and robust Apollo backing drive strong performance.ARI
Investor presentation9 Mar 2026 - Shareholders to vote on $9B asset sale to Athene, revised management fees, and future strategy.ARI
Proxy Filing9 Mar 2026 - Portfolio sale prompts asset value maximization and strategic review, with shareholder vote pending.ARI
Proxy Filing12 Feb 2026 - 2025 net income was $114M; full loan portfolio sale to Athene at 99.7% of commitments.ARI
Q4 202511 Feb 2026 - Stockholders to vote on $9B asset transfer to Athene, aiming to enhance value and efficiency.ARI
Proxy Filing10 Feb 2026 - Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy.ARI
Proxy Filing6 Feb 2026 - $9B real estate loan portfolio acquired with robust oversight and long-term investment focus.ARI
Proxy Filing6 Feb 2026 - $9B loan portfolio sale at 99.7% unlocks $1.4B cash, validates book, and enables strategic review.ARI
Status update3 Feb 2026 - Q2 distributable earnings $0.35/share; $90M CECL reserve expected for healthcare loan.ARI
Q2 20242 Feb 2026